Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cigna (CI – Research Report), Vertex Pharmaceuticals (VRTX – ...

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

The therapy involves taking stem cells out of a patient's bone marrow and editing a gene in the cells in a laboratory and ...

Design Therapeutics' GeneTAC platform is revolutionizing genetic disease treatment with small molecules and promising results ...

We recently published a list of 9 Stocks Jim Cramer Talked About. In this article, we are going to take a look at where ...

SG Americas Securities LLC decreased its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 17.9% during the 4th quarter, according to the company in its most recent disclosure with the ...

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day.

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

DeepSeek was tasked with selecting two stocks investors can buy now and hold long-term due to their growth potential.